Because it does not activate the hGH receptor (fully) and does not elevate IGF-1 in human trials, it avoids many of the growth-hormone-related side effects (such as insulin resistance) seen with full hGH therapy
Months 3 to 6 The biggest changes happen here
Advanced Laboratory Applications
When NNMT activity is elevated as documented in obese adipose tissue, several cancer types, and aged skeletal muscle intracellular NAD+ availability decreases, SAM availability decreases, and downstream sirtuin activity (particularly SIRT1 and SIRT3) is reduced
Daily Dose: 2.67 mg (equivalent to 10 units / 0.10 mL), maintained throughout the full cycle Frequency: Administer once daily via subcutaneous injection, ideally at the same time each day Cycle Duration: 4-16 weeks of continuous use, followed by a 24 week break to assess response and support receptor recovery Injection Volume: Approximately 0.10 mL per dose, well within typical comfort limits for subcutaneous delivery (generally under 1.01.5 mL) Syringe Guidance: A 0.3 mL (30-unit) U-100 insulin syringe is recommended for improved accuracy when measuring small volumes Storage Instructions Proper storage is essential to maintain peptide stability and integrity
